-
1.发明授权公开(公告)号：US06514496B1
公开(公告)日：2003-02-04
申请号：US09531183
申请日：2000-03-21
IPC分类号： A61K39395
CPC分类号： A61K9/0075 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/1658 , A61K9/1688 , A61K9/1694 , A61K39/395 , A61M15/0086 , Y10S514/951
摘要： This invention relates to dispersible antibody compositions and methods for preparing and using these compositions. In particular, the present invention relates to dry powder dispersible antibody compositions wherein antibody conformation is preserved. The compositions have good powder dispersibility and other desirable characteristics for pulmonary delivery of therapeutic antibodies.
摘要翻译： 本发明涉及可分散的抗体组合物以及制备和使用这些组合物的方法。 特别地，本发明涉及其中保护抗体构象的干粉分散抗体组合物。 组合物具有良好的粉末分散性和用于肺部递送治疗性抗体的其它期望特征。
-
公开(公告)号：US6019968A
公开(公告)日：2000-02-01
申请号：US951312
申请日：1997-10-16
IPC分类号： A61K9/14 , A61K9/00 , A61K9/12 , A61K9/16 , A61K9/72 , A61K31/70 , A61K31/715 , A61K38/00 , A61K38/23 , A61K38/28 , A61K38/55 , A61K38/57 , A61K39/395 , A61M11/00 , A61M15/00 , A61M16/00 , A61P5/12 , A61P11/00 , A61P37/04
CPC分类号： A61K9/1617 , A61K38/28 , A61K38/57 , A61K9/0075 , A61K9/1623 , A61K9/1652 , A61K9/1658 , A61K9/1688 , A61K9/1694 , A61K9/1635 , A61M15/0086 , A61M2205/073
摘要： This invention relates to dispersible antibody compositions and methods for preparing and using these compositions. In particular, the present invention relates to dry powder dispersible antibody compositions wherein antibody conformation is preserved. The compositions have good powder dispersibility and other desirable characteristics for pulmonary delivery of therapeutic antibodies.
-
公开(公告)号：US5994314A
公开(公告)日：1999-11-30
申请号：US422563
申请日：1995-04-14
CPC分类号： A61K9/0075 , A61K31/7088 , A61K47/48053 , A61K47/48815 , A61K47/48853 , A61K48/00 , A61K9/1272 , A61K9/1658 , B82Y5/00 , A61K9/1617 , A61K9/1623
摘要： A dry powder composition comprises insoluble nucleic acid constructs dispersed within with a hydrophilic excipient material, where the powder particles have an average size in the range from 0.5 .mu.m to 50 .mu.m. Nucleic acid constructs may comprise bare nucleic acid molecules, viral vectors, or vesicle structures. The hydrophilic excipient material will be selected to stabilize the nucleic acid molecules in the constructs, enhance dispersion of the nucleic acid in dry powder aerosols, and enhance wetting of the nucleic acid constructs as they are delivered to moist target locations within the body.
摘要翻译： 干粉组合物包含分散在亲水赋形剂材料中的不溶性核酸构建体，其中粉末颗粒的平均尺寸范围为0.5μm至50μm。 核酸构建体可以包含裸核酸分子，病毒载体或囊泡结构。 将选择亲水赋形剂材料以稳定构建体中的核酸分子，增强核酸在干粉气溶胶中的分散，并且当核酸构建体递送至身体内的潮湿目标位置时增强其核酸结构的润湿。
-
4.发明申请Devices, Compositions and Methods for the Pulmonary Delivery of Aerosolized Medicaments 审中-公开用于气雾剂的肺部输送的装置，组合物和方法公开(公告)号：US20070042048A1
公开(公告)日：2007-02-22
申请号：US11426927
申请日：2006-06-27
申请人： Robert Platz , John Patton , Linda Foster , Mohammed Eljamal
发明人： Robert Platz , John Patton , Linda Foster , Mohammed Eljamal
CPC分类号： A61K9/0075 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/1658 , A61K9/1688 , A61K9/1694 , A61K31/7088 , A61K31/727 , A61K38/1793 , A61K38/215 , A61K38/23 , A61K38/28 , A61K38/29 , A61K38/57 , A61K47/544 , A61K48/00 , A61M15/0033 , A61M15/0045 , A61M15/0051 , A61M15/0086 , A61M2202/064 , A61M2205/0233 , A61M2205/073 , B82Y5/00 , C12N2799/022 , Y10S514/958 , A61K2300/00
摘要： According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (% w) water, usually below about 5% w and preferably less than about 3% w; a particle size of about 1.0-5.0 μm mass median diameter (MMD), usually 1.0-4.0 μm MMD, and preferably 1.0-3.0 μm MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 μm mass median aerodynamic diameter (MMAD), usually 1.5-4.5 μm MMAD, and preferably 1.5-4.0 MMAD. Such composition are of pharmaceutical grade purity.
摘要翻译： 根据本发明，提供了可分散干粉末药物基组合物，包括其制造方法和干粉分散装置。 可分散的干粉末药物基组合物是具有小于约10重量％（％w）水的水分含量，通常低于约5％w，优选小于约3％w的组合物; 粒径约1.0-5.0μm质量中值粒径（MMD），通常为1.0-4.0mg MMD，优选为1.0-3.0mg MMD; 递送剂量约> 30％，通常> 40％，优选> 50％，最优选> 60％; 和气溶胶颗粒大小分布为约1.0-5.0μm质量中值空气动力学直径（MMAD），通常为1.5-4.5μmMMAD，优选为1.5-4.0MMAD。 这种组合物具有药物级纯度。
-
公开(公告)号：US07097827B2
公开(公告)日：2006-08-29
申请号：US10242714
申请日：2002-09-13
CPC分类号： A61K9/0075 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/1658 , A61K9/1688 , A61K9/1694 , A61K31/7088 , A61K31/727 , A61K38/1793 , A61K38/215 , A61K38/23 , A61K38/28 , A61K38/29 , A61K38/57 , A61K47/544 , A61K48/00 , A61M15/0033 , A61M15/0045 , A61M15/0051 , A61M15/0086 , A61M2202/064 , A61M2205/0233 , A61M2205/073 , B82Y5/00 , C12N2799/022 , Y10S514/958 , A61K2300/00
摘要： According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (% w) water, usually below about 5% w and preferably less than about 3% w; a particle size of about 1.0-5.0 μm mass median diameter (MMD), usually 1.0-4.0 μm MMD, and preferably 1.0-3.0 μm MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 μm mass median aerodynamic diameter (MMAD), usually 1.5-4.5 μm MMAD, and preferably 1.5-4.0 MMAD. Such composition are of pharmaceutical grade purity.
-
6.发明授权Compositions and methods for the pulmonary delivery of aerosolized medicaments 失效用于气雾化药物肺部递送的组合物和方法公开(公告)号：US06673335B1
公开(公告)日：2004-01-06
申请号：US09616236
申请日：2000-07-14
IPC分类号： A61K912
CPC分类号： A61K9/0075 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1652 , A61K9/1658 , A61K9/1694 , A61K38/21 , A61K38/215 , A61K38/28 , A61K47/544 , A61M15/0033 , A61M15/0045 , A61M15/0051 , A61M15/0086 , A61M2202/064 , A61M2205/0233 , A61M2205/073 , B82Y5/00
摘要： According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (%w) water, usually below about 5%w and preferably less than about 3%w; a particle size of about 1.0-5.0 &mgr;m mass median diameter (MMD), usually 1.0-4.0 &mgr;m MMD, and preferably 1.0-3.0 &mgr;m MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 &mgr;m mass median aerodynamic diameter (MMAD), usually 1.5-4.5 &mgr;m MMAD, and preferably 1.5-4.0 &mgr;m MMAD. Such compositions are of pharmaceutical grade purity.
摘要翻译： 根据本发明，提供了可分散干粉末药物基组合物，包括其制造方法和干粉分散装置。 可分散的干粉末药物基组合物是具有小于约10重量％（％w）水的水分含量，通常低于约5％w，优选小于约3％w的组合物; 粒径约1.0-5.0μm质量中值粒径（MMD），通常为1.0-4.0mg MMD，优选为1.0-3.0mg MMD; 递送剂量约> 30％，通常> 40％，优选> 50％，最优选> 60％; 和气溶胶粒度分布为约1.0-5.0μm质量中值空气动力学直径（MMAD），通常为1.5-4.5μmMMAD，优选为1.5-4.0mg MMAD。 这样的组合物具有药物级纯度。
-
7.发明授权Devices compositions and methods for the pulmonary delivery of aerosolized medicaments 失效用于肺部递送雾化药物的装置组合物和方法公开(公告)号：US06509006B1
公开(公告)日：2003-01-21
申请号：US09427075
申请日：1999-10-26
IPC分类号： A61K912
CPC分类号： A61K9/0075 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1658 , A61K38/21 , A61K38/215 , A61K38/28 , A61K47/544 , A61M15/0033 , A61M15/0045 , A61M15/0051 , A61M2202/064 , A61M2205/0233 , A61M2205/073 , B82Y5/00
摘要： According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (% w) water, usually below about 5% w and preferably less than about 3% w; a particle size of about 1.0-5.0 &mgr;m mass median diameter (MMD), usually 1.0-4.0 &mgr;m MMD, and preferably 1.0-3.0 &mgr;m MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 &mgr;m mass median aerodynamic diameter (MMAD), usually 1.5-4.5 &mgr;m MMAD, and preferably 1.5-4.0 MMAD. Such composition are of pharmaceutical grade purity.
摘要翻译： 根据本发明，提供了可分散干粉末药物基组合物，包括其制造方法和干粉分散装置。 可分散的干粉末药物基组合物是具有小于约10重量％（％w）水的水分含量，通常低于约5％w，优选小于约3％w的组合物; 粒径约1.0-5.0μm质量中值粒径（MMD），通常为1.0-4.0mg MMD，优选为1.0-3.0mg MMD; 递送剂量约> 30％，通常> 40％，优选> 50％，最优选> 60％; 和气溶胶颗粒大小分布为约1.0-5.0μm质量中值空气动力学直径（MMAD），通常为1.5-4.5μmMMAD，优选为1.5-4.0MMAD。 这种组合物具有药物级纯度。
-
8.发明授权Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin 失效干粉α1-抗胰蛋白酶的肺部给药方法和装置
公开(公告)号：US5780014A
公开(公告)日：1998-07-14
申请号：US617512
申请日：1996-03-13
申请人： Mohammed Eljamal , John S. Patton
发明人： Mohammed Eljamal , John S. Patton
IPC分类号： A61K9/14 , A61K9/00 , A61K9/12 , A61K9/16 , A61K9/72 , A61K31/70 , A61K31/715 , A61K35/16 , A61K38/00 , A61K38/23 , A61K38/28 , A61K38/55 , A61K38/57 , A61K39/395 , A61M11/00 , A61M15/00 , A61M16/00 , A61P5/12 , A61P11/00 , A61P37/04
CPC分类号： A61K9/0075 , A61K38/28 , A61K38/57 , A61K9/1617 , A61K9/1623 , A61K9/1652 , A61K9/1658 , A61K9/1688 , A61K9/1694 , A61K9/1635 , A61M15/0086 , A61M2205/073
摘要： Methods are provided for administering .alpha.1-antitrypsin dry powder pulmonarily to a patient. In these methods, .alpha.1-antitrypsin is provided in a dry powder form which is aerosolized and administered to the patient. Apparatus are also provided for carrying out these methods. These methods and apparatus are may generally be used in the treatment of patients suffering from .alpha.1-antitrypsin deficiency and the functional derangements of emphysema.
摘要翻译： 提供了向患者肺部给予α1-抗胰蛋白酶干粉的方法。 在这些方法中，α1-抗胰蛋白酶以干粉形式提供，其被雾化并施用于患者。 还提供了用于实施这些方法的装置。 这些方法和装置通常可用于治疗患有α1-抗胰蛋白酶缺乏症的患者和肺气肿的功能紊乱。
-
9.发明申请COMPOSITIONS AND METHODS FOR THE PULMONARY DELIVERY OF AEROSOLIZED MEDICAMENTS 审中-公开用于气溶胶药物递送的组合物和方法公开(公告)号：US20070122418A1
公开(公告)日：2007-05-31
申请号：US11627884
申请日：2007-01-26
申请人： Robert Platz , John Patton , Linda Foster , Mohammed Eljamal
发明人： Robert Platz , John Patton , Linda Foster , Mohammed Eljamal
IPC分类号： A61K39/00
CPC分类号： A61K9/0075 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/1658 , A61K9/1688 , A61K9/1694 , A61K31/7088 , A61K31/727 , A61K38/1793 , A61K38/215 , A61K38/23 , A61K38/28 , A61K38/29 , A61K38/57 , A61K47/544 , A61K48/00 , A61M15/0033 , A61M15/0045 , A61M15/0051 , A61M15/0086 , A61M2202/064 , A61M2205/0233 , A61M2205/073 , B82Y5/00 , C12N2799/022 , Y10S514/958 , A61K2300/00
摘要： Therapeutic dried compositions are described. The composition is in solid dose form and includes a polyol and an immunogenic agent.
摘要翻译： 描述了治疗性干燥的组合物。 组合物为固体剂型，包括多元醇和免疫原性试剂。
-
10.发明授权Compositions and methods for the pulmonary delivery of aerosolized macromolecules 失效用于气雾化大分子肺部递送的组合物和方法公开(公告)号：US06797258B2
公开(公告)日：2004-09-28
申请号：US10072430
申请日：2002-02-08
IPC分类号： A61K900
CPC分类号： A61K9/0075 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/1658 , A61K9/1688 , A61K9/1694 , A61K31/7088 , A61K31/727 , A61K38/1793 , A61K38/215 , A61K38/23 , A61K38/28 , A61K38/29 , A61K38/57 , A61K47/544 , A61K48/00 , A61M15/0033 , A61M15/0045 , A61M15/0051 , A61M15/0086 , A61M2202/064 , A61M2205/0233 , A61M2205/073 , B82Y5/00 , C12N2799/022 , Y10S514/958 , A61K2300/00
摘要： According to the subject invention, dispersible dry powder pharmaceutical-based compositions are provided, including methods for their manufacture and dry powder dispersion devices. A dispersible dry powder pharmaceutical-based composition is one having a moisture content of less than about 10% by weight (% w) water, usually below about 5% w and preferably less than about 3% w; a particle size of about 1.0-5.0 &mgr;m mass median diameter (MMD), usually 1.0-4.0 &mgr;m MMD, and preferably 1.0-3.0 &mgr;m MMD; a delivered dose of about >30%, usually >40%, preferably >50%, and most preferred >60%; and an aerosol particle size distribution of about 1.0-5.0 &mgr;m mass median aerodynamic diameter (MMAD), usually 1.5-4.5 &mgr;m MMAD, and preferably 1.5-4.0 &mgr;m MMAD. Such compositions are of pharmaceutical grade purity.
摘要翻译： 根据本发明，提供了可分散干粉末药物基组合物，包括其制造方法和干粉分散装置。 可分散的干粉末药物基组合物是具有小于约10重量％（％w）水的水分含量，通常低于约5％w，优选小于约3％w的组合物; 粒径约1.0-5.0μm质量中值粒径（MMD），通常为1.0-4.0mg MMD，优选为1.0-3.0mg MMD; 递送剂量约> 30％，通常> 40％，优选> 50％，最优选> 60％; 和气溶胶粒度分布为约1.0-5.0μm质量中值空气动力学直径（MMAD），通常为1.5-4.5μmMMAD，优选为1.5-4.0mg MMAD。 这样的组合物具有药物级纯度。
-
-
-
-
-
-
-
-
-
搜索结果
17 条记录 (耗时 0.021 秒)
